ELI LILLY AND COMPANY |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 883.9 USD | -0.24% |
|
+0.62% | +51.63% |
| 09:45pm | Weight-loss drug Zepbound resolves sleep apnea in up to 52% of patients, Lilly says | RE |
| 06:22am | Eli Lilly Sues More Wellness Centers, Medical Spas Over Unauthorized Tirzepatide Sales | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
Pharmaceuticals
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
886
USD
Average target price
855.4
USD
Spread / Average Target
-3.45%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +51.63% | 798B | |
| +41.51% | 633B | |
| -5.10% | 356B | |
| +19.90% | 328B | |
| +9.95% | 304B | |
| +17.66% | 244B | |
| +3.39% | 227B | |
| +10.75% | 216B | |
| +6.99% | 166B | |
| -3.65% | 157B |
- Stock Market
- Equities
- LLY Stock
- News Eli Lilly and Company
- Eli Lilly to Invest Another $5.3 Billion in Indiana Manufacturing Site
